IDXG OTC
Interpace Biosciences, Inc.
1W: -6.4%
1M: -17.2%
3M: -27.3%
YTD: +0.8%
1Y: +46.3%
3Y: +14.3%
5Y: -87.0%
$6.00
-0.39 (-6.10%)
Weekly Expected Move ±6.7%
$5
$6
$6
$6
$7
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$39M
-17.5% ▼
5Y CAGR: +3.6%
Gross Profit
$24M
-19.4% ▼
5Y CAGR: +17.6%
Operating Income
$4M
-49.6% ▼
Net Income
$25M
+266.7% ▲
EPS (Diluted)
$0.90
+125.0% ▲
EBITDA
$4M
-51.1% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $41M | $32M | $40M | $47M | $39M |
| YoY Growth | +27.5% | -22.9% | +26.3% | +16.7% | -17.5% |
| Cost of Revenue | $23M | $14M | $16M | $17M | $15M |
| Gross Profit | $18M | $18M | $24M | $30M | $24M |
| Gross Margin | 43.4% | 57.3% | 59.4% | 63.8% | 62.3% |
| R&D Expenses | $2M | $703K | $636K | $676K | $642K |
| SG&A Expenses | $24M | $20M | $20M | $21M | $19M |
| Operating Expenses | $30M | $22M | $21M | $22M | $20M |
| Operating Income | -$12M | -$4M | $3M | $8M | $4M |
| Operating Margin | -28.4% | -12.1% | 7.0% | 17.3% | 10.5% |
| Interest Expense | $1M | $1M | $1M | $659K | -$168K |
| Income Before Tax | -$15M | -$6M | $1M | $7M | $4M |
| Tax Expense | -$667K | $29K | $17K | $4K | -$21M |
| Net Income | -$15M | -$6M | $802K | $7M | $25M |
| Net Margin | -35.7% | -18.4% | 2.0% | 14.3% | 63.5% |
| EPS (Diluted) | $-3.57 | $-1.38 | $0.18 | $0.40 | $0.90 |
| EBITDA | -$1M | -$2M | $4M | $8M | $4M |
| Shares Outstanding | 4M | 4M | 4M | 4M | 28M |